Can boosting the SORLA gene protect the brain from tau damage in Alzheimer's?
Novel Neuroprotective Roles for the Alzheimer's Disease Risk Gene SORLA in Tau Pathology and Pathogenesis
Researchers are testing whether increasing levels of the SORLA gene can reduce tau-related brain damage for people at risk for or living with Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanford Burnham Prebys Medical Discovery Institute NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11237569 on NIH RePORTER |
What this research studies
From a patient perspective, the team raises SORLA levels in laboratory models that develop tau-related brain changes to see if those changes are reduced. They examine brain tissue for signs of tau phosphorylation, inflammation, and synapse loss using protein analysis and microscopic staining. The researchers compare animals with and without extra SORLA and look at related molecules such as APOE and the complement protein C1q to understand how SORLA might protect brain cells. Although the work is currently in animal and lab samples, the findings could guide future therapies or trials for people with Alzheimer's.
Who could benefit from this research
Good fit: People with Alzheimer's disease or those at higher genetic risk for Alzheimer's (for example, with SORL1 variants) would be the kinds of patients most likely to benefit from future therapies based on this work.
Not a fit: Patients without Alzheimer’s disease or whose symptoms are caused by non-tau processes are less likely to benefit directly from these findings in the near term.
Why it matters
Potential benefit: If successful, this work could point to new ways to slow or prevent tau-related brain damage in Alzheimer's by boosting SORLA or its pathways.
How similar studies have performed: Previous studies have shown SORLA can protect against amyloid-related problems, but using SORLA to counter tau pathology is a newer and less-tested approach.
Where this research is happening
La Jolla, United States
- Sanford Burnham Prebys Medical Discovery Institute — La Jolla, United States (Active)
Researchers
- Principal investigator: Huang, Timothy Yikai — Sanford Burnham Prebys Medical Discovery Institute
- Study coordinator: Huang, Timothy Yikai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.